Article citationsMore>>
M. Marchand, P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, Y. Humblet, J.-L. Canon, C. Laurent, J.-M. Naeyaert, R. Plagne, R. Deraemaeker, A. Knuth, E. Jager, F. Brasseur, J. Herman, P. G. Couiae and T. Boon, “Tumor Regression Responses in Melanoma Patients Treated with a Peptide Encoded by Gene MAGE-3,” International Journal of Cancer, Vol. 63, No. 6, 1995, pp. 883-885.
doi:10.1002/ijc.2910630622
has been cited by the following article:
-
TITLE:
Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses
AUTHORS:
Kristian M. Hargadon
KEYWORDS:
Melanoma; Tumor Immunotherapy; Dendritic Cell; Tumor Antigen; T Cell; Vaccine; Adoptive Transfer
JOURNAL NAME:
Journal of Cosmetics, Dermatological Sciences and Applications,
Vol.3 No.2A,
June
20,
2013
ABSTRACT:
Melanoma is the most aggressive form
of skin cancer and accounts for the vast majority of skin cancer-related
deaths. Its ability to metastasize quickly, often before diagnosis, makes this
cancer difficult to treat with traditional therapies. The identification of
anti-melanoma immune responses in patients and the discovery of tumor antigens
targeted by these immune responses have paved the way for immunotherapy as a
novel approach to treating this cancer. In this review, the major
immunotherapies targeting these melanoma tumor antigens are discussed. The
advantages and limitations of peptide-, protein-, and gene-based vaccination
maneuvers and adoptive cell transfer therapies are emphasized. Recent insights
into melanoma immune evasion strategies are also highlighted, with particular
focus on how our increasing knowledge of tumor/immune cell interactions is
driving the development of novel immunotherapeutic strategies for the treatment
of melanoma.
Related Articles:
-
Xinyou Zhang, Yongchang Huang
-
Hamidreza Saiedi
-
Hamidreza Saiedi
-
Wei Li, Zhaojun Qian, Huiyu Li
-
Catherine Mahihu